Pujita Roy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pujita Roy has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Munir Ahmad
Survey of Pakistan, Pakistan
3 shared publications - Bimol Chandra Das
Trine University, USA
1 shared publication - Deepta Majumder
Department of Cardiology Bangladesh Medical University Dhaka Bangladesh
1 shared publication - Fahadul Alam
Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA
1 shared publication - Hafiz Tareq Abdullah Khan
University of West London, UK
1 shared publication - Hrishik Iqbal
Quest Bangladesh Biomedical Research Center, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 7 November 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-18
Choices and challenges in end-of-life care and decision-making: a nationwide cross-sectional study in Bangladesh
End-of-life (EoL) care is the final phase of life (typically the last year when death is imminent), distinct from but related to palliative care, which provides broader support for serious illness. In many low- and middle-income countries, including Bangladesh, end-of-life care remains underdeveloped. Cultural norms, socio-economic disparities, limited palliative care infrastructure, and lack of healthcare provider training further complicate informed decision-making at EoL. This study aimed to evaluate EoL care awareness, preferences, and decision-making factors among critically ill older adult patients in Bangladesh. This cross-sectional study was conducted from September 2024 to February 2025 across eight administrative divisions of Bangladesh, involving 1,270 patients aged ≥ 50 years with chronic or advanced illnesses, including hospitalized patients aged ≥ 18 years with life expectancy < 1 year from private (n = 368), public (n = 439), and community (n = 463) settings. Divisional hospitals provided hospital-based data, while three randomly selected sub-districts per division ensured proportional community representation. Data was collected using structured questionnaires adapted from validated international tools, capturing socio-demographics, and end-of-life (EoL) awareness, preferences, and experiences. Predictors of end-of-life preferences were examined using multiple logistic regression analysis. Only 6.93% had health insurance, with just 1.7% in community settings. Palliative care awareness was highest in private hospitals (70%), followed by public (31%) and community settings (7.1%) (p < 0.01). Advance care planning awareness and documentation were lowest in community patients (p < 0.01). Older adults (≥ 60 years) were more likely to prefer home care (OR = 2.96, p = 0.004), avoid hospitalization (OR = 17.55, p < 0.001), and choose home death (OR = 10.29, p < 0.001). Greater understanding of palliative care (OR = 7.38, p < 0.001) and hospice comfort (OR = 25.26, p < 0.001) strongly predicted documentation of end-of-life preferences. Family openness varied widely (private: 81%, public: 21%, community: 7.1%). Proxy appointment was significantly associated with prior discussions (AOR = 4.11), while trust in healthcare providers reduced the likelihood (AOR = 0.39). Profound disparities in end-of-life awareness and preferences exist across healthcare settings in Bangladesh, driven by socio-economic, cultural, and institutional factors. Efforts must prioritize patient choice through enhanced communication, culturally sensitive advance care planning, and expanding home-based palliative options to honor care preferences at the end of life.
- 7 November 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-18
Open AccessChoices and challenges in end-of-life care and decision-making: a nationwide cross-sectional study in Bangladesh
End-of-life (EoL) care is the final phase of life (typically the last year when death is imminent), distinct from but related to palliative care, which provides broader support for serious illness. In many low- and middle-income countries, including Bangladesh, end-of-life care remains underdeveloped. Cultural norms, socio-economic disparities, limited palliative care infrastructure, and lack of healthcare provider training further complicate informed decision-making at EoL. This study aimed to evaluate EoL care awareness, preferences, and decision-making factors among critically ill older adult patients in Bangladesh. This cross-sectional study was conducted from September 2024 to February 2025 across eight administrative divisions of Bangladesh, involving 1,270 patients aged ≥ 50 years with chronic or advanced illnesses, including hospitalized patients aged ≥ 18 years with life expectancy < 1 year from private (n = 368), public (n = 439), and community (n = 463) settings. Divisional hospitals provided hospital-based data, while three randomly selected sub-districts per division ensured proportional community representation. Data was collected using structured questionnaires adapted from validated international tools, capturing socio-demographics, and end-of-life (EoL) awareness, preferences, and experiences. Predictors of end-of-life preferences were examined using multiple logistic regression analysis. Only 6.93% had health insurance, with just 1.7% in community settings. Palliative care awareness was highest in private hospitals (70%), followed by public (31%) and community settings (7.1%) (p < 0.01). Advance care planning awareness and documentation were lowest in community patients (p < 0.01). Older adults (≥ 60 years) were more likely to prefer home care (OR = 2.96, p = 0.004), avoid hospitalization (OR = 17.55, p < 0.001), and choose home death (OR = 10.29, p < 0.001). Greater understanding of palliative care (OR = 7.38, p < 0.001) and hospice comfort (OR = 25.26, p < 0.001) strongly predicted documentation of end-of-life preferences. Family openness varied widely (private: 81%, public: 21%, community: 7.1%). Proxy appointment was significantly associated with prior discussions (AOR = 4.11), while trust in healthcare providers reduced the likelihood (AOR = 0.39). Profound disparities in end-of-life awareness and preferences exist across healthcare settings in Bangladesh, driven by socio-economic, cultural, and institutional factors. Efforts must prioritize patient choice through enhanced communication, culturally sensitive advance care planning, and expanding home-based palliative options to honor care preferences at the end of life.
- Open Access
- 6 October 2025
- Published by Universa Medicina in Universa Medicina
- Vol. 44 (3)
Bortezomib in multiple myeloma management
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells, leading to complications such as bone lesions, renal dysfunction, and immune suppression. Over the past three decades, its incidence has risen significantly, attributed to factors such as aging populations and improved diagnostic methods. Treatment strategies have evolved considerably, transitioning from alkylating agents and high-dose chemotherapy to targeted therapies, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Bortezomib, a first-in-class PI, has revolutionized MM management by inhibiting proteasome activity, thereby inducing apoptosis in malignant plasma cells. This review evaluates the efficacy, safety, and clinical applications of bortezomib, both as monotherapy and in combination with dexamethasone, IMiDs, and conventional chemotherapies. Key clinical trials, such as VISTA and SUMMIT, demonstrate its superiority over traditional regimens, improving response rates and survival outcomes. However, its use is associated with adverse effects, including peripheral neuropathy, hematologic toxicities, and gastrointestinal disturbances, necessitating dose modifications and supportive care. Emerging combinations with monoclonal antibodies and novel agents further enhance therapeutic potential, though optimal sequencing remains under investigation. Systematic literature search was performed using PubMed and Cochrane to identify relevant studies on the applications of bortezomib. The search was inclusive of all publications up to May 2025, without restriction by publication year, to ensure a thorough review of research on bortezomib. Studies focusing on multiple myeloma (MM) and the efficacy of bortezomib were prioritized. A broad set of keywords was employed reflecting the diverse applications of bortezomib in MM treatment. The search strategy was designed to capture a wide range of relevant studies. By synthesizing evidence from 77 studies, this review highlights bortezomib’s pivotal role in MM treatment while addressing challenges in toxicity management. Future research should focus on refining combination strategies and minimizing side effects to maximize long-term patient outcomes.
- 6 October 2025
- Published by Universa Medicina in Universa Medicina
- Vol. 44 (3)
Open AccessBortezomib in multiple myeloma management
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells, leading to complications such as bone lesions, renal dysfunction, and immune suppression. Over the past three decades, its incidence has risen significantly, attributed to factors such as aging populations and improved diagnostic methods. Treatment strategies have evolved considerably, transitioning from alkylating agents and high-dose chemotherapy to targeted therapies, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Bortezomib, a first-in-class PI, has revolutionized MM management by inhibiting proteasome activity, thereby inducing apoptosis in malignant plasma cells. This review evaluates the efficacy, safety, and clinical applications of bortezomib, both as monotherapy and in combination with dexamethasone, IMiDs, and conventional chemotherapies. Key clinical trials, such as VISTA and SUMMIT, demonstrate its superiority over traditional regimens, improving response rates and survival outcomes. However, its use is associated with adverse effects, including peripheral neuropathy, hematologic toxicities, and gastrointestinal disturbances, necessitating dose modifications and supportive care. Emerging combinations with monoclonal antibodies and novel agents further enhance therapeutic potential, though optimal sequencing remains under investigation. Systematic literature search was performed using PubMed and Cochrane to identify relevant studies on the applications of bortezomib. The search was inclusive of all publications up to May 2025, without restriction by publication year, to ensure a thorough review of research on bortezomib. Studies focusing on multiple myeloma (MM) and the efficacy of bortezomib were prioritized. A broad set of keywords was employed reflecting the diverse applications of bortezomib in MM treatment. The search strategy was designed to capture a wide range of relevant studies. By synthesizing evidence from 77 studies, this review highlights bortezomib’s pivotal role in MM treatment while addressing challenges in toxicity management. Future research should focus on refining combination strategies and minimizing side effects to maximize long-term patient outcomes.
- 1 April 2025
- Published by IGI Global Scientific Publishing
- p. 305-330
Spatial Data Governance for Healthcare Metaverse
The healthcare metaverse, leveraging VR and AR, revolutionizes medical services, education, and research by creating immersive, interactive environments. However, integrating spatial health data poses challenges in data accuracy, security, privacy, and ethical considerations, necessitating frameworks. The chapter proposes a framework for spatial data governance in the healthcare metaverse, focusing on patient control over health information. It includes rigorous data security and privacy protocols, ensures transparency and accountability, addresses ethical concerns, and encourages collaboration among stakeholders. This framework aims to uphold responsible data practices, protect patient privacy, and improve the effectiveness of healthcare services within the metaverse.
- 1 April 2025
- Published by IGI Global Scientific Publishing
- p. 305-330
Spatial Data Governance for Healthcare Metaverse
The healthcare metaverse, leveraging VR and AR, revolutionizes medical services, education, and research by creating immersive, interactive environments. However, integrating spatial health data poses challenges in data accuracy, security, privacy, and ethical considerations, necessitating frameworks. The chapter proposes a framework for spatial data governance in the healthcare metaverse, focusing on patient control over health information. It includes rigorous data security and privacy protocols, ensures transparency and accountability, addresses ethical concerns, and encourages collaboration among stakeholders. This framework aims to uphold responsible data practices, protect patient privacy, and improve the effectiveness of healthcare services within the metaverse.
- 14 March 2025
- Published by IGI Global Scientific Publishing
- p. 255-286
Secure Data Sharing in Healthcare
Integrating blockchain and digital twins in healthcare offers a secure and dynamic way to share patient data. Blockchain technology secures data through encryption, audit trails, and giving patients control over access. Digital twins create virtual patients to simulate health conditions and personalize treatments. This integration improves data sharing across healthcare providers by establishing common formats and breaking down data silos, which ultimately benefits patients with better care coordination, privacy, and personalized medicine. However, challenges like scalability, complying with regulations, and building trust among users need to be addressed for this technology to be widely adopted.
- 14 March 2025
- Published by IGI Global Scientific Publishing
- p. 255-286
Secure Data Sharing in Healthcare
Integrating blockchain and digital twins in healthcare offers a secure and dynamic way to share patient data. Blockchain technology secures data through encryption, audit trails, and giving patients control over access. Digital twins create virtual patients to simulate health conditions and personalize treatments. This integration improves data sharing across healthcare providers by establishing common formats and breaking down data silos, which ultimately benefits patients with better care coordination, privacy, and personalized medicine. However, challenges like scalability, complying with regulations, and building trust among users need to be addressed for this technology to be widely adopted.
- 8 November 2024
- Published by IGI Global Scientific Publishing
- p. 299-318
OpenStreetMap and Digital Health: Enhancing Patient Care and Healthcare Delivery
This chapter explored the applications of OpenStreetMap (OSM) in digital health, highlighting improvements in patient navigation, resource mapping, and epidemic response. Integrating OSM data into digital health platforms enhances patient journeys by providing real-time navigation and access to public transportation options. It can help in locating urgent care centers and mapping specialist providers, chronic condition support services, and mental health resources. During epidemics, OSM supports disease surveillance and vaccination site mapping. OSM can also help to identify underserved areas to promote telehealth and incorporate social determinants of health for a holistic approach. Challenges such as data accuracy, consistency, and completeness can be addressed through community moderation, partnerships, and supplementary data sources. Ensuring data currency through real-time updates and user feedback mechanisms can further enhance the reliability of OSM-based digital health applications.
- 8 November 2024
- Published by IGI Global Scientific Publishing
- p. 299-318
OpenStreetMap and Digital Health: Enhancing Patient Care and Healthcare Delivery
This chapter explored the applications of OpenStreetMap (OSM) in digital health, highlighting improvements in patient navigation, resource mapping, and epidemic response. Integrating OSM data into digital health platforms enhances patient journeys by providing real-time navigation and access to public transportation options. It can help in locating urgent care centers and mapping specialist providers, chronic condition support services, and mental health resources. During epidemics, OSM supports disease surveillance and vaccination site mapping. OSM can also help to identify underserved areas to promote telehealth and incorporate social determinants of health for a holistic approach. Challenges such as data accuracy, consistency, and completeness can be addressed through community moderation, partnerships, and supplementary data sources. Ensuring data currency through real-time updates and user feedback mechanisms can further enhance the reliability of OSM-based digital health applications.